Pharma Journalist -

Pfizer announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE (palbociclib) in combination…
Read More...

The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in…
Read More...

Sinovant Sciences and Roivant Sciences announced the launch of Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics…
Read More...

The WIRB-Copernicus Group's (WCG) Clinical Services Division announces the acquisition of Analgesic Solutions, LLC, the global leader in the development of new pain medications and in…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, today resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and…
Read More...

Editas Medicine and BlueRock Therapeutics announced a strategic research collaboration and cross-licensing agreement to combine their respective genome editing and cell therapy…
Read More...

Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched with a $50 million Series A. Atlas Venture founded,…
Read More...

ViiV Healthcare presented three year results from the SWORD 1 & 2 studies, demonstrating that 84% (432/513) of participants who switched from their current three- or four-drug…
Read More...

Cellectis announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for…
Read More...

Clinical stage biotechnology company QUE Oncology announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot…
Read More...